Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06842186 | A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity | PHASE1 | RECRUITING | 296 | — | — | Jan 31, 2025 | Dec 1, 2027 | Jun 2, 2026 | 6 | United States, Moldova +2 |
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Part A: Experimental WVE-007 (Dose 1) or Placebo Part B Pre-T2D: Experimental WVE-007 (Dose 1) or Placebo |
| Cohort 2 | EXPERIMENTAL | Part A: Experimental WVE-007 (Dose 2) or Placebo Part B Pre-T2D: Experimental WVE-007 (Dose 2) or Placebo |
| Cohort 3 | EXPERIMENTAL | Part A: Experimental WVE-007 (Dose 3) or Placebo |
| Cohort 4 | EXPERIMENTAL | Part A: Experimental WVE-007 (Dose 4) or Placebo Part B T2D: Experimental WVE-007 (Dose 4) or Placebo |
| Cohort 5 | EXPERIMENTAL | Part A: Experimental WVE-007 (Dose 5) or Placebo Part B T2D: Experimental WVE-007 (Dose 5) or Placebo |
| Name | Type | Description |
|---|---|---|
| WVE-007 | DRUG | Stereopure siRNA oligonucleotide |
Inclusion Criteria: Part A * Male and female participants aged 18 to 60 years * BMI 28 to 35 kg/m2 which has been stable (±5%) for the previous 3 to 6 months (based on participant self-report or medical records). For participants considered for enrollment in a cohort expansion, BMI 28 to 40 kg/ m2 ...